Abstract Three transcription factors, Krox20 (EGR2), Oct6 (SCIP/Tst1) and Sox10, are considered necessary for transition from the nonmyelinating to the myelinating stage of Schwann cell development. We immunohistochemically studied Oct6 expression in peripheral nerve specimens from 25 patients with various diseases including CharcotMarie-Tooth disease type 1A (CMT1A). Oct6 was present in cytoplasm of Schwann cells associated with normal-appearing myelinated nerve fibers, but not in nuclei. Expression was seen in nuclei of Schwann cells in the early phase of acute axonal degeneration; nuclear expression peaked at the regenerative stage. Schwann cells forming "onion bulbs" expressed Oct6 in chronic inflammatory demyelinating polyneuropathy (CIDP), but showed minimal expression in CMT1A, reflecting their proliferative activity in CIDP. Nerves showing chronic axonal loss had no expression. Oct6, then, may be a marker for dedifferentiation of adult Schwann cells and active nerve regeneration.
Introduction
During development of peripheral nerves, immature Schwann cells (SC) migrate along outgrowing axons, proliferate, and segregate with axons until numbers of axons and SC in a given internodal cross section are evenly matched [33] . After a one-to-one relationship between axon and myelinating SC is established, myelination of large-caliber axons is initiated. Although little is known about the cellular signals that initiate myelination, three transcription factors, Krox20 (EGR2), Oct6 (SCIP/Tst1), and Sox10, are considered necessary for transition from the nonmyelinating to the myelinating stage in Schwann cell development [4, 14, 15, 17, 28, 30, 35] . Myelination cannot occur in a Krox20 null mutant, while Oct6 is required for correct timing of myelination. Although the precise roles of individual transcription factors in myelination are not known, mutation of Krox20 has been shown to cause Charcot-Marie-Tooth disease type 1 (CMT1) [32] .
CMT1 often is caused by duplication of the gene encoding PMP22 and also can be caused by a mutation in one of four genes: PMP22, P0, connexin32 and Krox20 [20, 23] . While molecular mechanisms differ, the clinical phenotypes are quite similar. In contrast to Krox20, the other three genes; PMP22, P0 and connexin32, are structural proteins of myelin. Mild overexpression of PMP22 mRNA has been reported in patients with CMT1A [11, 34] . In a transgenic model that overexpresses PMP22, development of Schwann cells is arrested at the premyelinating stage, showing failure of myelination while the cells continue to express genes encoding structural myelin proteins [24] . By analogy, Krox20 and Oct6 might be involved in the myelination disorder in CMT1A, the most common form of hereditary neuropathy. We immunohistochemically investigated whether Oct6 expression was altered in CMT1A and in other peripheral neuropathies.
Materials and methods
The subjects were 25 patients with peripheral neuropathies (Table 1) ; five each with CMT1A, chronic inflammatory demyelinating polyneuropathy (CIDP); acute vasculitic axonal neuropathy; severe axonal neuropathy of unknown origin that clinically stabilized in the years following initial acute or subacute progression; and, active axonal regeneration following vasculitis or correction of vitamin deficiency. Also included were three control subjects who initially were suspected to have neuropathy but showed no evidence of neuropathy in routine histological studies. In CMT1A patients du-plication of the PMP22 gene (17p11.2-12) was detected by interphase-fluorescence in situ hybridization [18, 19] . Diagnosis of CIDP followed research criteria established by the American Academy of Neurology [1] . Informed consent was obtained from all patients after full explanation about nerve biopsy was given.
Immunohistochemistry
The sural nerve biopsy specimens were fixed in 4% paraformaldehyde, embedded in paraffin and cut at a thickness of 2 µm. Sections were deparaffinized in xylene and rehydrated through graded ethanol solutions, and then were subjected to microwave irradiation in Target retrieval solution (DAKO). Sections then were incubated in 0.6% H 2 O 2 for 10 min. Nonspecific binding was blocked by incubation with 1% nonfat milk and 2% normal swine serum in 0.05 M TRIS-buffered saline (TBS, pH 7.45). Sections then were incubated with the primary antibody, goat anti-Oct6 IgG (Santa Cruz Biotechnology, Calif.). Immunoreactivity was visualized by an avidin-biotin complex method, followed by light counterstaining with hematoxylin. Negative controls involved either the omission of primary antibody or neutralization of primary antibody by preincubation with a fivefold excess of synthetic Oct6 peptide (Santa Cruz) in a small volume of phosphate-buffered saline (PBS) for 2 h at room temperature.
Adjacent sections were incubated with anti-S-100 rabbit polyclonal antibody (DAKO) to identify Schwann cells, which was detected by fluorescence microscopy using rhodamine-labeled antirabbit IgG.
Western blot analysis
To determine the specificity of the antibody, Western blotting was performed using selected nerve specimens (five with CMT1A, three with axonal regeneration, and three controls). Cells were lysed by immersion of cryostat sections in 200 µl of ice-cold extraction buffer (50 mM TRIS-HCl at pH 7.4, 1% NP-40, 1 mM EDTA, 1 mg/ml PMSF, 5 mg/ml leupeptin, 5 mg/ml pepstatin, and 5 mg/ml aprotinin) for 30 min. After lysates were centrifuged at 10,000 g for 10 min at 4°C, the supernatant was collected and protein content was determined. Amounts of protein then were equalized at 20 µg/lane by adding appropriate volumes of Laemmli reagent. Samples were electrophoresed through a 5-15% gradient sodium dodecyl sulfate (SDS)-polyacrylamide gel (Bio-Rad). Proteins were transferred to PVDF membranes (Immobilon, Millipore), which then were saturated with 1% nonfat dry milk in TBS with 0.2 M Tween20 to block nonspecific binding, followed by reaction with primary antibodies against Oct6. The bound antibodies were immunodetected by an enhanced chemiluminescence kit (ECL; Amersham). Anti-vimentin antibody was used as an internal control to normalize differences in amount of Schwann cell protein among samples. Densitometric analysis was done using Scion Images (US National Institute of Health; NIH). Density of the Oct6 band was determined as a ratio to the vimentin band in each case. Figure 1 shows representative toluidine blue-stained Eponembedded sections together with immunohistochemical staining for Oct6 in paraffin-embedded sections.
Results

Immunohistochemistry
In control nerves (Fig. 1A) , paraffin sections showed patchy immunostaining in Schwann cell cytoplasm, which was seen outside of the myelin sheath surrounding both large and small fibers. A mean of 5,360 immunoreactive cells per mm 2 was counted. Oct6 immunoreactivity was abolished by preincubation of the antibody with the synthetic peptide. Nuclear staining was rare. Nonmyelinating Schwann cells showed no staining. Nerves showing acute axonal degeneration generally showed weak immunoreactivity for Oct6 (Fig. 1B) ; some fibers showed staining of Schwann cell cytoplasm and appeared consistent with surviving fibers. In contrast, nerves showing diffuse axonal loss, an advanced stage of axonal degeneration, showed intense staining in denervated Schwann cell clusters 204 ( Fig. 1C) , with a mean of 30% of endoneurial nuclei showing reactivity for Oct6. Nuclear immunoreactivity for Oct6 was most striking in nerves showing active regeneration ( Fig. 1D) , being apparent in 45-62% of endoneurial nuclei. Almost all cells with nuclear staining were Schwann cells, which was confirmed by immunostaining with anti-S-100 antibody (Fig. 2) . The density of immunoreactive cells was mean of 870/mm 2 . In contrast to the marked nuclear staining, the cytoplasm of Schwann cells associated with regenerating small myelinated fibers was not reactive for Oct6. Nerve specimens from patients with CMT1A showed Oct6 immunostaining localized to Schwann cell cytoplasm surrounding the myelin sheath; rare nuclei including those in "onion bulbs" were stained in both early and advanced stages (Fig. 1F, G) . In one sample from a patient with advanced CMT1A that contained only a few myelinated fibers per nerve fascicle, the few cells showing staining for Oct6 had the morphological features of fibroblasts. In contrast, samples from patients with CIDP included numerous Oct6-positive cells in onion-bulb formations, some showing nuclear immunoreactivity (Fig. 1E) .
In the patients with chronic axonopathy, almost no immunoreactivity for Oct6 was present in any of these specimens (Fig. 1H) .
Western blot
Oct6 protein was detected in all patients at an apparent molecular mass of 48 kDa. The density of the Oct6 band relative to that of the vimentin band was significantly greater in the group with axonal regeneration (mean 0.36) than in the control group (mean 0.12; P<0.01 by the Mann-Whitney U test) (Fig. 3 ).
Discussion
As a transcription factor, Oct6 acts in the nucleus to regulate expression of certain genes. Oct6 is known to be necessary for transition from the nonmyelinating to the myelinating stage in Schwann cell development [2] . In this study, Oct6 protein was identified in human peripheral nerves. Oct6 immunoreactivity was present in the cytoplasm but not nuclei of Schwann cells associated with myelinated fibers of intact control nerve. In this normal state, Oct6 present in the cytoplasm did not appear to participate significantly in cell function. However, in the early phase of axonal degeneration, Oct6 stained intensely in acutely denervated Schwann cell clusters, sometimes in nuclei. In active nerve regeneration, most Schwann cell nuclei were positive for Oct6. These results indicate that in acute axonal degeneration breakdown of myelin leads Schwann cells to up-regulate Oct6, while at the time of nerve regeneration Oct6 is translocated to the nucleus where it promotes transcription of certain genes, possibly those encoding myelin proteins. During myelin formation, Schwann cell cytoplasm does not show Oct6, but after myelination Oct is expressed constitutively in Schwann cell cytoplasm outside of the myelin sheath.
In contrast to active axonal degeneration and regeneration, Schwann cell bands in cases of chronic axonal loss showed no immunoreactivity for Oct6. Loss of axonSchwann cell interactions may shift Schwann cells to the premyelinating stage, a dedifferentiated state phenotypically similar to that of nonmyelinating Schwann cells [21, 28] . Axonal contact enables the ensheathing Schwann cell to transform to the differentiated state in which it expresses protein components of the myelin sheath. Failure of axonal contact as in chronic axonal loss may restrict Schwann cells to the molecular phenotype in which myelinrelated proteins are down-regulated. Denervated Schwann cells have a phenotype similar to that of nonmyelinating Schwann cells [5, 8, 16, 27] . However, our study indicates that the phenotype of recently denervated Schwann cells includes expression of Oct6, which differs from the absence of expression in chronically denervated cells. Absent expression of Oct6 in chronic axonal loss therefore reflects long-standing loss of axonal-Schwann cell interaction.
Most of the excessive numbers of cells in onion bulbs in some CIDP patients express Oct6, indicating proliferative activity of Schwann cells. In CMT1A, however, Schwann cells forming onion bulbs are more similar to nonmyelinating Schwann cells in terms of showing little expression of Oct6, although a secondary Schwann cell proliferation appears to occur following demyelination. Schwann cell phenotype in onion bulbs in CMT1A has been reported to differ from that in patients with CIDP in that low-affinity nerve growth factor (LNGF-R) [12] , NCAM [13] and PMP22 [25] were overexpressed in CMT1A. In the early developmental stages of P0 knockout mice, expression of NCAM and LNGF-R is increased [6] . In MAG-knockout mice, onion bulbs expressed LNGF-R, NCAM, and glial fibrillary acidic protein (GFAP) [8] . Thus, altered Schwann cell differentiation may occur commonly if the gene dose for a myelin protein is altered [10] . D-type cyclins are required for the initial steps in cell division, and cyclin translocation into nuclei is crucial for promotion of cell proliferation [3] . Like normal myelinating Schwann cells in wild-type rats, remyelinating Schwann cells in a PMP22-transgenic rat, a model for CMT1A, show perinuclear cyclin D1 expression [3] . Schwann cells with nuclear cyclin D1 expression, as well as proliferating Schwann cells, were identified in demyelinated axonal segments. Supernumerary Schwann cells in onion bulbs did not express cyclin D1 and were not proliferating [3] . This finding is in agreement with essentially absent expression of Oct6 in onion bulbs in CMT1A, in contrast to acquired neuropathies. The relationship between altered Schwann cell differentiation and suppressed Oct6 in CMT1A requires further investigation.
Neuregulins (NRG), the only trophic factors known to support Schwann cell survival, have potential application in treatment of patients with chronic neuropathies [5, 7, 9, 29, 31] . NRG-1 is required for Krox20 expression [22] . We found expression of one NRG isoform, NRG-β1, to be increased in axons in the early phase of axonal degeneration in nerve biopsy specimens from patients with neuropathy [26] . Regenerating nerve fibers contained abundant NRG-β1 in axons, but nerves from patients with chronic axonal neuropathy showed less. Axon-derived NRG, then, might trigger Schwann cells to activate transcription factors involved in myelin formation. This requires further investigation.
